Vision Genomics
Vision Genomics develops personalized therapeutics for age-related macular degeneration by matching drug effects to disease-specific genomic and transcriptomic signatures. The company uses a biotech precision-medicine platform that integrates gene expression, genetic and epigenetic databases with drug-target and perturbation datasets. Core technologies include advanced genomic and transcriptomic analysis, parametric and machine learning algorithms for drug screening, and pharmacogenomic-aware prioritization. The platform is positioned for collaborations with ophthalmology researchers, clinics, and drug developers addressing AMD and other age-related ocular diseases.
Vision Genomics
Vision Genomics develops personalized therapeutics for age-related macular degeneration by matching drug effects to disease-specific genomic and transcriptomic signatures. The company uses a biotech precision-medicine platform that integrates gene expression, genetic and epigenetic databases with drug-target and perturbation datasets. Core technologies include advanced genomic and transcriptomic analysis, parametric and machine learning algorithms for drug screening, and pharmacogenomic-aware prioritization. The platform is positioned for collaborations with ophthalmology researchers, clinics, and drug developers addressing AMD and other age-related ocular diseases.
TL;DR
Company: Vision Genomics
Founded: 2014
Industry: Biotechnology
Focus: Precision therapeutics for age-related macular degeneration using genomic and transcriptomic signatures
Known investor (recorded): Deep Knowledge Group (seed, 2015-04-15)
Company Overview
Problem Domain
Age-related macular degeneration and other age-related ocular diseases; matching therapeutics to disease-specific genomic/transcriptomic signatures.
Founded
2014
Industry
Biotechnology